amylin glp 1 dual agonist Amycretin — a novel obesity treatment that targets both GLP-1 and receptors — has shown early success in phase testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD Once-Monthly Incretin-, Amylin-, and THRβ-Targeting

Zhou, Z

Anker SD, Butler J, Filippatos G, et al

Repeat freeze-thaw cycles should be avoided because peptide bond degradation and aggregation can compromise assay results

In a pivotal phase 2 randomized trial published in the New England Journal of Medicine, orforglipron, a once-daily oral nonpeptide GLP-1RAs, demonstrated substantial and sustained weight loss among adults with obesity, with efficacy comparable to injectable agents and an acceptable safety profile [35]

(1983b)

So, although osteoarthritis and rheumatoid arthritis are different in some aspects of their pathology, treatments for these diseases may benefit arthrofibrosis patients